Ontology highlight
ABSTRACT:
SUBMITTER: Wang Z
PROVIDER: S-EPMC11003264 | biostudies-literature | 2024
REPOSITORIES: biostudies-literature
Wang Zhulin Z Huang Chunyao C Fan Wenbo W Sun Shaowu S Li Kaiyuan K Liu Xu X Pu Jiangtao J Zhang Guoqing G Li Xiangnan X
Frontiers in oncology 20240325
Given their good antitumor effects, epidermal growth factor receptor (<i>EGFR</i>) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for <i>EGFR</i>-sensitive mutations, including exon 19 deletions and exon 21 L858R mutations. <i>EGFR</i> fusion mutations and <i>EGFR</i> amplification are very rare in non-small cell lung cancer (NSCLC). We describe 2 patients with NSCLC harboring <i>EGFR</i> fusion mutations (<i>EGFR-MACF1</i> and <i>EGFR-GNAT3</i>) combined with <i>EGFR</i> ampl ...[more]